Finanzen von Electra Therapeutics, Inc. Common stock (ETRA)ETRAElectra Therapeutics, Inc. Common stock

In the context of the broader market, ETRA competes directly with industry leaders such as ACRS and DBVT. With a market capitalization of $548.68M, it holds a significant position in the sector. When comparing efficiency, ETRA's gross margin of N/A stands against ACRS's 10.80% and DBVT's N/A. Such benchmarking helps identify whether Electra Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Electra Therapeutics has a price-to-book ratio of -21.688, indicating negative equity, and both its PE and forward PE ratios are 0, suggesting no earnings are currently being generated.